Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a small-molecule, orally bioavailable multi-target tyrosine kinase inhibitor (TKI) that inhibits VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency, showing IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (Xie et al., 2018). It exhibits strong anti-angiogenic activity by blocking endothelial cell migration and tube formation in vitro (https://doi.org/10.1111/cas.13536). Compared to sunitinib and sorafenib, Anlotinib demonstrates superior selectivity and efficacy against key angiogenic targets. Pharmacokinetic studies reveal high bioavailability, broad tissue distribution, and significant plasma protein binding in preclinical species. APExBIO provides validated Anlotinib (hydrochloride) (SKU C8688) for use in cell-based and mechanistic cancer research (product page).

Biological Rationale

Angiogenesis is critical for tumor growth, invasion, and metastasis. Tumors larger than ~1 mm³ require new blood vessel formation to sustain further expansion (Xie et al., 2018). Vascular endothelial growth factor (VEGF) and its receptor VEGFR2 are central regulators of this process. Platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) pathways also contribute to angiogenic signaling. Targeting these pathways disrupts the vascular support essential for tumor progression. Small-molecule TKIs offer an alternative to monoclonal antibodies, providing oral bioavailability and the capacity to simultaneously block multiple pro-angiogenic signals. Anlotinib (hydrochloride) was developed to address the need for more potent and selective multi-kinase inhibitors with favorable safety and pharmacokinetic profiles (https://doi.org/10.1111/cas.13536).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib binds to the ATP-binding site of receptor tyrosine kinases, including VEGFR2, PDGFRβ, and FGFR1. This binding inhibits kinase phosphorylation and blocks downstream signaling cascades, notably the ERK pathway. The compound demonstrates strong inhibition of VEGF-, PDGF-BB-, and FGF-2-induced endothelial cell migration and capillary-like tube formation in vitro. In human EA.hy 926 vascular endothelial cells, Anlotinib inhibits cell migration and tube formation in a concentration-dependent manner. The compound also impairs microvessel outgrowth from rat aortic explants and reduces vascular density in tumor xenografts in vivo (Xie et al., 2018). Compared to sunitinib, sorafenib, and nintedanib, Anlotinib achieves superior inhibition of these pro-angiogenic processes at lower concentrations. ERK pathway inhibition further contributes to its anti-proliferative effects on endothelial cells.

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 kinase activity with an IC₅₀ of 5.6 ± 1.2 nM under cell-free conditions (Xie et al., https://doi.org/10.1111/cas.13536).
• Inhibitory potency against PDGFRβ and FGFR1 is 8.7 ± 3.4 nM and 11.7 ± 4.1 nM, respectively (Xie et al., https://doi.org/10.1111/cas.13536).
• Blocks VEGF-induced ERK phosphorylation and proliferation in HUVEC with picomolar efficacy (Xie et al., https://doi.org/10.1111/cas.13536).
• Demonstrates superior anti-angiogenic activity vs. sunitinib, sorafenib, and nintedanib in comparative in vitro and in vivo models (Xie et al., https://doi.org/10.1111/cas.13536).
• Oral administration in rats and dogs yields bioavailability of 28–58% and 41–77%, respectively, with rapid absorption (Lou et al., product page).
• High plasma protein binding (93% in humans) and extensive tissue distribution, including lung, liver, kidney, heart, and tumors (Lou et al., product page).
• Median lethal dose (LD₅₀) >1700 mg/kg in 14-day oral toxicity studies; no significant organ or genetic toxicity observed (Lou et al., product page).

This article extends the bench-marking and optimization strategies found in “Optimizing Tumor Angiogenesis and Viability Assays with Anlotinib (hydrochloride)” by providing direct molecular and comparative efficacy data for mechanistic clarity.

For strategic and mechanistic advances, see “Anlotinib Hydrochloride: Redefining Tumor Angiogenesis Inhibition”, which this article updates with new pharmacokinetic and selectivity benchmarks.

Applications, Limits & Misconceptions

Anlotinib (hydrochloride) is used in research models to study anti-angiogenic mechanisms, inhibition of endothelial cell migration, and modulation of ERK signaling. Typical assays involve human vascular endothelial cells (EA.hy 926) and cell-free kinase inhibition protocols. The compound is suited for capillary tube formation, migration assays, and tumor xenograft studies. Due to its robust selectivity, Anlotinib is a preferred reagent in oncology research workflows (related article). This article clarifies selectivity and application range beyond basic kinase inhibition.

Common Pitfalls or Misconceptions

• Not suitable for diagnostic or medical use. Anlotinib (hydrochloride) from APExBIO is strictly intended for research applications (product page).
• Direct anti-proliferative effects on tumor cells require higher (micromolar) concentrations than those needed for anti-angiogenic effects (Xie et al., 2018).
• Not all tumor types rely on VEGFR2/PDGFRβ/FGFR1-driven angiogenesis; efficacy is context-dependent.
• Compound should be stored at -20°C to maintain stability for research use.
• Results from animal models may not translate directly to clinical efficacy.

Workflow Integration & Parameters

Anlotinib (hydrochloride) integrates easily into standard angiogenesis and migration assay workflows. Recommended concentrations for endothelial cell assays range from 1 to 100 nM for VEGFR2-dependent processes. For kinase panel profiling, use cell-free systems with ATP concentrations near K_m to reflect physiological conditions. In vivo, oral dosing protocols should align with published pharmacokinetic data. Tissue distribution studies support use in models where blood-brain barrier penetration is relevant. The C8688 kit from APExBIO ensures validated material for reproducible research (product page). For extended mechanistic and troubleshooting workflows, this guide details advanced assay design and experimental controls, complementing the molecular data presented here.

Conclusion & Outlook

Anlotinib hydrochloride represents a benchmark multi-target tyrosine kinase inhibitor for research on tumor angiogenesis and tyrosine kinase signaling pathways. Its high potency, selectivity, and favorable pharmacokinetics make it suitable for mechanistic, translational, and preclinical cancer research. Ongoing clinical evaluation will clarify its therapeutic impact, but for laboratory studies, APExBIO’s Anlotinib (hydrochloride) (SKU C8688) provides a validated, high-purity standard. Further advances in angiogenesis research will benefit from its use in reproducible, well-controlled experimental designs (mechanistic review).